• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Section Contents Menu

Vaccines

First Committee Meeting, September 8, 2009 - MenHibrix

 

MenHibrix – STN 125363/0
First Committee Meeting
September 8, 2009
 
 
 
Agenda:
  1. Review milestones
  2. Discuss review assignments
  3. Discuss review strategies
Milestones:
 
Application Received:                            August 12, 2009
Committee Assignment                         August 25, 2009
1st Committee Meeting                           September 8, 2009
Filing Meeting                                                   September 25, 2009 (via e-mail)
Filing Action/Deficiencies Identified                    October 11, 2009
Action Due Date:                                              June 12, 2010
 
Committee Assigned:
 
Chair                                                   Joseph Temenak, Ph.D.
 
Committee Members
Clinical Reviewer/Labeling                     Meghan Ferris, M.D.
Product CMC/Serology                          Mustafa Akkoyunlu, M.D. Ph.D, 
Product CMC                                       Willie Vann, Ph.D.
Product CMC                                       Daron Freedberg, Ph.D
Product CMC                                       Milan Blake, Ph.D.
Product/CMC                                       Tina Roecklein, MS
Product/CMC                                       James (Erich) Keller, Ph.D.
Product/CMC                                       Michael Schmitt, Ph.D.
Facilities/DMPQ                                   Joseph George
Facilities/DMPQ                                   Sean Byrd                    
Advertising/ Promotional Labeling          Maryann Gallagher
Clinical Statistical Reviewer                   Barbara Krasnicka, Ph.D.
Assays Statistical Reviewer                   Tsai-Lien Lin, Ph.D.
Epidemiology                                         David Menschik, M.D., MPH
DPQ/Lot Testing Plan                           Rajesh Gupta, Ph.D.
DPQ/Lot Testing Plan                           Karen Campbell
Lot Release                                          Joe Quander III
BiMo                                                    Robert Wesley
Electronic Integrity Reviewer                 David Schwab, MSIS
 
RPMs/RC
DVRPA Regulatory Project Manager    Jason Humbert
DVRPA Regulatory Project Manager    David Staten, MPH
DBPAP Regulatory Coordinator                        Jennifer Bridgewater, MPH
 
 
Discussion Items:
 
After an account of participants in the meeting was conducted, Dr. Joseph Temenak introduced himself to the committee and provided an overview of the BLA and the associated milestones and timelines.
 
Regarding Bioresearch Monitoring (BiMo), the clinical reviewer will contact BiMo to determine which sites for the pivotal U.S. study (Hib-MenCY-TT-009/010) will be investigated. Additionally, sites from study Hib-MenCY-TT-007/008 conducted in Australia may be investigated as this study provides data for administration of MenHibrix with MMR/Varicella vaccines. The clinical review team will provide 3 sites for possible inspection in the U.S. and notify BiMo if any of the data in the Australian study which may warrant an inspection. BiMo stated that they need at least a 60 (preferably a 90) day notice for any foreign inspections. As a early notice, the product review division stated that the site in the Netherlands where the ‘C’ and ‘Y’ bactericidal assays are conducted will be of interest with regard to BiMo inspection. The product division will recommend the assay sites to BiMo and will send one reviewer to accompany BiMo on the inspection.
 
Regarding the pre-licensure inspection, DMPQ stated that the tetanus toxoid purification occurs in November at a facility -----(b)(4)--------- that has not been previously inspected.  DMPQ inquired as to who will accompany the facility inspectors. The product division will discuss internally.
 
The topic of VRBPAC was discussed and whether this BLA will need to go before the Advisory Committee. Because of the indication and the dosing schedule of 2, 4, 6 and 12-15 months of age, this application may need to go to VRBPAC.
 
A meeting with PeRC will be scheduled after the application is filed.
 
DPQ stated that the lot release protocols will be discussed after the reviews are drafted (after mid-cycle). DBPAP will figure out the critical pieces and be in touch with DPQ through the coordination of the RPMs regarding lot testing.
 
The Product Release Branch (PRB) will need to be included on communications regarding the request for samples and reagents from GSK.
 
The proprietary name review will be conducted initially in September/early October and then again prior to approval. APLB is aware of the proposed proprietary name and will communicate to the Chair, clinical reviewer and the RPMs the recommendation regarding the proprietary name.
 
Reviewers were reminded to be clear about what information was reviewed in their memos. Reviewers were also reminded that any additional information provided in response to a telecon or e-mail should be referenced in the review memo.
 
Dr. Temenak advised everyone to be aware of the filing decision e-mail coming soon.
The meeting concluded.